de
Ingo Schmidt-Wolf
© UKBonn
Prof. Dr. Ingo Schmidt-Wolf

Webseite

Zugehörigkeiten
  • Abteilung für Integrierte Onkologie, Universitätsklinikum Bonn
Forschungsschwerpunkte
  • cancer
  • cell therapy
  • immunotherapy
The research group "Prof. Schmidt-Wolf, Department of Integrated Oncology" headed by Prof. Ingo Schmidt-Wolf is part of the Center for Integrated Oncology (CIO) Bonn, a strategic partnership linking CIO ABCD Network: Aachen-Bonn-Cologne-Düsseldorf, Germany. The aim of the group is to understand the cellular and molecular mechanisms associated with T cell-mediated immunological processes. In the framework of clinically applicable adoptive T cell immunotherapies (e.g. cytokine-induced killer (CIK) cell therapy and its derivatives such as dendritic cells (DC-CIK cell therapy), chimeric antigen receptors (CAR-CIK) and natural killer T (NKT) cell therapy), the group is consistently striving to develop new treatment options in the field of immuno-oncology. Based on the idea of isolating the patient's own immune cells, then expanding (ex vivo) and reinfusing them, the group has been involved in several success stories in the field of cancer immunotherapy.
Ausgewählte Publikationen

Sharma A, Schmidt-Wolf IGH (2021) 30 years of CIK cell therapy: recapitulating the key breakthroughs and future perspective. J Exp Clin Cancer Res. 2021 Dec 9;40(1 ):388. doi: 10.1186/s13046-021-02184-2. PMID: 34886895 Free PMC article.

Zhang Y, Schmidt-Wolf IGH (2020) Ten-year update of the international registry on cytokine-induced killer cells in cancer immunotherapy. J Cell Physiol. 2020 Dec;235(12):9291 -9303. doi: 10.1002/jcp.29827. Epub 2020 Jun 2. PMID: 32484595 Review.

Schmeel LC, Schmeel FC, Coch C, Schmidt-Wolf IG (2015) Cytokine- induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 2015 May;141 (5):839-49. doi: 10.1007 /s00432-014-1864-3. Epub 2014 Nov 8. PMID: 25381063.

Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mause/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991 Jul 1;174(1):139-49. doi: 10.1084/jem.174.1 .139. PMID: 1711 560 Free PMC article.

Ingo Schmidt-Wolf
© UKBonn
Prof. Dr. Ingo Schmidt-Wolf

Webseite

-